Telix Pharmaceuticals (TLX) Non-Current Deffered Revenue (2023 - 2024)
Telix Pharmaceuticals (TLX) posted quarterly Non-Current Deffered Revenue of $2.3 million for Q4 2024, down 72.96% year-on-year from $8.6 million in Q1 2024, and down 72.96% on a QoQ basis from $8.6 million in Q4 2023.
Telix Pharmaceuticals (TLX) Non-Current Deffered Revenue (2023 - 2024) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Non-Current Deffered Revenue for 2 consecutive years, with $2.3 million the latest figure, recorded in Q4 2024.
- Quarterly Non-Current Deffered Revenue fell 72.96% year-over-year to $2.3 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.3 million (down 72.96% YoY) and the FY2024 annual result came in at $2.0 million, down 75.53% from the prior year.
- Non-Current Deffered Revenue declined to $2.3 million in Q4 2024 per TLX's latest filing, from $8.6 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for TLX reached as high as $8.6 million in Q4 2023 and fell as low as $2.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Telix Pharmaceuticals | 3.55 Bn | 3.41 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.32 Mn |
| Dec 31, 2023 | 8.59 Mn |